The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Empirical Antifungal Therapy With Itraconazole
Official Title: Retrospective Observation of Empirical Antifungal Therapy With Itraconazole
Study ID: NCT01706562
Brief Summary: The purpose of this study is to investigate the overall success rate of itraconazole intravenous treatment for a period of more than 7 days.
Detailed Description: This is a retrospective study ie, a study that looks backward in time, usually using medical records and interviews with patients who are already known to have a disease, in patients with itraconazole intravenous prescription as an empirical (based on practical experience) antifungal agent. This study collects baseline information about underlying disease, sign of fungal infection, neutropenia (a decrease in white blood cells), neutropenic fever duration and the reason for discontinuation. Neutropenia is defined as a neutrophil (white blood cell) count of ≤500 cells/mm3 or a count of ≤1000 cells/mm3 with a predicted decrease to ≤500 cells/mm3. Fever is defined as a body temperature ≥38.3 Celsius degrees at least once a day with no definite external factor or a body temperature of ≥38 Celsius degrees continued for at least 1 hour.
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Name: Janssen Korea, Ltd., Korea Clinical Trial
Affiliation: Janssen Korea, Ltd., Korea
Role: STUDY_DIRECTOR